When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...
Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...
Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...
Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...
After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...
A Prolog-based solver for the classic “Tents and Trees” logic puzzle. Developed for the Logic for Programming course (2023–2024), this project demonstrates constraint logic programming, recursive ...
🔒 Monte Carlo simulator comparing 4 replay attack defenses for IoT/wireless systems | Evaluates Rolling Counter, Sliding Window, Challenge-Response under packet loss & reordering | 200+ runs, 95% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback